Maravai LifeSciences Enters Material Definitive Agreement

Ticker: MRVI · Form: 8-K · Filed: Sep 12, 2024 · CIK: 1823239

Maravai Lifesciences Holdings, Inc. 8-K Filing Summary
FieldDetail
CompanyMaravai Lifesciences Holdings, Inc. (MRVI)
Form Type8-K
Filed DateSep 12, 2024
Risk Levelmedium
Pages3
Reading Time4 min
Key Dollar Amounts$0.01, $167M
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, definitive-agreement

Related Tickers: MRVI

TL;DR

Maravai just signed a big deal, details TBD.

AI Summary

Maravai LifeSciences Holdings, Inc. announced on September 10, 2024, that it has entered into a material definitive agreement. The filing does not disclose specific details of the agreement, the counterparty, or any associated financial figures.

Why It Matters

This filing indicates a significant new contract or partnership for Maravai LifeSciences, which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and impact of the material definitive agreement.

Key Players & Entities

  • MARAVAI LIFESCIENCES HOLDINGS, INC. (company) — Registrant
  • September 10, 2024 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • San Diego, California (location) — Principal executive offices

FAQ

What is the nature of the material definitive agreement entered into by Maravai LifeSciences?

The filing does not specify the nature of the material definitive agreement.

Who is the counterparty to this material definitive agreement?

The filing does not disclose the name of the counterparty to the agreement.

What is the effective date of this material definitive agreement?

The earliest event reported is September 10, 2024, which is the date of the report and the date of the earliest event.

Are there any financial terms or dollar amounts associated with this agreement disclosed in the filing?

No specific financial terms or dollar amounts related to the agreement are disclosed in this filing.

Does this filing provide any information on the expected impact of this agreement on Maravai LifeSciences' business?

The filing states it is an 'Entry into a Material Definitive Agreement' but does not elaborate on the expected impact.

Filing Stats: 923 words · 4 min read · ~3 pages · Grade level 14.1 · Accepted 2024-09-12 15:58:42

Key Financial Figures

  • $0.01 — which registered Class A Common Stock, $0.01 par value MRVI The Nasdaq Stock Market
  • $167M — ent of a commitment fee of 0.65% of the $167M revolving facility. Our revolving credi

Filing Documents

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement On September 10, 2024, we amended our Existing Credit Agreement (as defined below), enabling us to extend the maturity date of our revolving credit facility by five years (subject to springing maturity provisions based on the maturity of the term loan facility which currently matures in October 2027), upon satisfaction of customary closing conditions including the payment of a commitment fee of 0.65% of the $167M revolving facility. Our revolving credit facility remains undrawn and available to us. A more detailed summary of the amendment follows. On September 10, 2024, certain subsidiaries (the " Loan Parties ") of Maravai LifeSciences Holdings, Inc. entered into a Third Amendment to Credit Agreement (the " Third Amendment ") to amend the Credit Agreement, dated as of October 19, 2020 (as amended by the First Amendment to Credit Agreement, dated as of August 11, 2021, and the Second Amendment to Credit Agreement, dated as of January 19, 2022, the " Existing Credit Agreement "), among Maravai Intermediate Holdings, LLC, Cygnus Technologies, LLC and TriLink Biotechnologies, LLC, as Borrowers, Maravai Topco Holdings, LLC, each lender from time to time party thereto and Morgan Stanley Senior Funding, Inc., as administrative agent and collateral agent, to, among other things and subject to the satisfaction of certain customary conditions set forth in the Third Amendment, extend the maturity date of the revolving credit facility provided under the Existing Credit Agreement from October 2025 to the date that is five years from the effective date of the amendments to the Existing Credit Agreement provided under the Third Amendment (subject to springing maturity provisions based on the maturity of the term loan facility provided under the Existing Credit Agreement). The amendments to the Existing Credit Agreement, including the extension to the maturity date of the revolving credit facility provided thereunder, wil

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. The following exhibits are furnished as part of this Current Report on Form 8-K: Exhibit No. Description of Exhibit 10.1 Third Amendment to Credit Agreement, dated September 10, 2024, among Maravai Intermediate Holdings, LLC, Cygnus Technologies, LLC, TriLink Biotechnologies, LLC, Maravai Topco Holdings, LLC, Morgan Stanley Senior Funding, Inc. and the other lenders and parties thereto. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MARAVAI LIFESCIENCES HOLDINGS, INC. Date: September 12, 2024 By: /s/ Kevin M. Herde Name: Kevin M. Herde Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.